| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-A*1101 & B2M & EBV (AVFDRKSDAK) | Biotinylated Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   | |||
| HLA-A*1101 & B2M & EBV (AVFDRKSDAK) | PE-Labeled Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Tetramer Protein | Human | HEK293 | $410.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifitegrast | SHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606 | Approved | Shire Development Llc | Xiidra | United States | Dry Eye Syndromes | Bausch And Lomb Inc | 2016-07-11 | Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia | Details |
